ImCheck Therapeutics
Created in 2015
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
552 9,503Global tags
Activities
Technologies
Entity types
Location
31 Chemin Joseph Aiguier, CS 70071 13402, MARSEILLE Cedex 20, 13009 Marseille, France
Marseille
France
Employees
Scale: 11-50
Estimated: 55
SIREN
812428142Engaged corporates
34
15 24Added in Motherbase
4 years, 4 months ago
biotech Value proposition
Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic
ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.
As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases.
Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
antibodies, immuno-oncology, Immune checkpoint Modulators, Auto-immunity, innate immunity, oncology, cancer, precision-based medicine, adaptative immunity, EVICTIONtrial, ICT01, and gamma-deltaTcellsOriginal language
Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic
ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.
As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases.
Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
Imchecktherapeutics.com: Imcheck Therapeutics
Imcheck Therapeutics : Opening new spaces in Immuno-Oncology.
https://imchecktherapeutics.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Le Journal des Entreprises Media, Newspaper Publishing | Le Journal des Entreprises Media, Newspaper Publishing | Other 3 Apr 2023 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 17 Jun 2020 23 Oct 2024 | | |
 P.Factory Business Consulting and Services | P.Factory Business Consulting and Services | Not capitalistic Not partnership Event 20 Jun 2019 | | |
 Grand Luminy Technopole Business Consulting and Services | Grand Luminy Technopole Business Consulting and Services | Not capitalistic Not partnership Event 10 Jun 2020 4 Oct 2023 | | |